Trial · NCT03834948
AO-176 in Multiple Solid Tumor Malignancies
NCT03834948, Phase 1, Phase 2, Completed, Arch Oncology
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. AO-176 in Multiple Solid Tumor Malignancies. Trials, record NCT03834948. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03834948
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- AO-176 in Multiple Solid Tumor Malignancies
- NCT number
- NCT03834948
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 57 participants, actual
- Lead sponsor
- Arch Oncology
- Conditions
- Solid Tumor
- Interventions
- AO-176, AO-176 + Paclitaxel, AO-176 + Pembrolizumab
- First posted
- 2019-02-08
- Last updated
- 2023-08-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety of AO-176 assessed by adverse events and laboratory abnormalities | Up to 12 months | Evaluate the safety of AO-176 measured by the number adverse events, serious adverse events and lab abnormalities. |
| Primary | Safety of AO-176 and paclitaxel assessed by adverse events and laboratory abnormalities | Up to 12 months | Evaluate the safety of AO-176 in combination with paclitaxel measured by the number adverse events, serious adverse events and lab abnormalities. |
| Primary | Safety of AO-176 and pembrolizumab assessed by adverse events and laboratory abnormalities | Up to 12 months | Evaluate the safety of AO-176 in combination with pembrolizumab measured by the number adverse events, serious adverse events and lab abnormalities. |
| Secondary | AO-176 anti-tumor activity assessed by changes in response criteria | Up to 12 months | Evaluate objective response rate of AO-176 using RECIST v1.1 and iRECIST. |
| Secondary | AO-176 + paclitaxel anti-tumor activity assessed by changes in response criteria | Up to 12 months | Evaluate objective response rate of AO-176 in combination with paclitaxel using RECIST v1.1 and iRECIST. |
| Secondary | AO-176 + pembrolizumab anti-tumor activity assessed by changes in response criteria | Up to 12 months | Evaluate objective response rate of AO-176 in combination with pembrolizumab using RECIST v1.1 and iRECIST. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33431660 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03834948
GET https://conductscience.org/api/trials/v1/NCT03834948/registered